{"id":3861,"date":"2016-01-08T22:08:15","date_gmt":"2016-01-08T22:08:15","guid":{"rendered":"https:\/\/www.missouriwestern.edu\/magazine\/?p=1277"},"modified":"2019-06-12T10:23:14","modified_gmt":"2019-06-12T15:23:14","slug":"incubator-tenant-sells-forms-new-company","status":"publish","type":"post","link":"https:\/\/www.missouriwestern.edu\/magazine\/2016\/01\/08\/incubator-tenant-sells-forms-new-company\/","title":{"rendered":"Incubator Tenant Sells; Forms New Company"},"content":{"rendered":"<p>Antibiotic technology developed by a tenant of the Innovation Stockyard in the Kit Bond Science and Technology Incubator was purchased by a newly formed pharmaceutical company. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sopharmia, Inc., founded by Larry Sutton, MD, PhD, announced the closing of a $3.3 million Series A venture capital financing round and the formation of Gladius Pharmaceuticals Inc. based in Montreal. Sopharmia\u2019s antibiotic technology is now wholly owned by Gladius Pharmaceuticals.<\/p>\n<p>Sopharmia\u2019s team, which did a large portion of their work at the campus\u2019s Innovation Stockyard, pioneered dual mechanism small molecule antibiotics that combine antibiotic functionality with activity against one of the main causes of antibiotic resistance.<\/p>\n<p>Although Sopharmia, Inc. \u201cgraduated\u201d from the Innovation Stockyard, Dr. Sutton and his team are orchestrating Gladius Pharmaceuticals\u2019 North American research and development operations from their new company Sopharmbique LLC that will also be housed in the Innovation Stockyard.<\/p>\n<p>\u201cThis financing enables us to accelerate the advancement of our lead compound,\u201d said Dr. Sutton. \u201cInnovation Stockyard has helped us through good times and bad. We\u2019re pleased to continue this relationship with them.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antibiotic technology developed by a tenant of the Innovation Stockyard in the Kit Bond Science and Technology Incubator was purchased by a newly formed pharmaceutical company. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sopharmia, Inc., founded by Larry Sutton, MD, PhD, announced the closing of a $3.3 million Series A venture capital financing round and the formation [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[19],"tags":[],"_links":{"self":[{"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/posts\/3861"}],"collection":[{"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/comments?post=3861"}],"version-history":[{"count":1,"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/posts\/3861\/revisions"}],"predecessor-version":[{"id":4235,"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/posts\/3861\/revisions\/4235"}],"wp:attachment":[{"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/media?parent=3861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/categories?post=3861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.missouriwestern.edu\/magazine\/wp-json\/wp\/v2\/tags?post=3861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}